AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes ...

AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for ...

AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

AbbVie has won expanded European approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with giant cell arteritis.

AbbVie today announced that the European Commission (EC) granted marketing authorization to RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in adult patients.

Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return ...

Goldman Sachs made significant rating changes across its U.S. biopharma coverage on Tuesday, upgrading the likes of Eli Lilly ...

Daiichi Sankyo-partnered anti-HER2 drug Enhertu (trastuzumab deruxtecan) has been cleared by the European Commission for use ...

Goldman Sachs analyst Asad Haider assumed coverage of AbbVie (ABBV) with a Neutral rating and $194 price target The company’s “strong” growth ...

In this wide and deep sector, though, there are some notable exceptions. Let's take a look at two outliers with dividend policies that have looked especially attractive lately -- pharmaceutical ...